(−)1‐(Benzofuran‐2‐yl)‐2‐propylaminopentane, [(−)BPAP], a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain
- 1 December 1999
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 128 (8) , 1723-1732
- https://doi.org/10.1038/sj.bjp.0702995
Abstract
1. The brain constituents beta-phenylethylamine (PEA) and tryptamine enhance the impulse propagation mediated transmitter release (exocytosis) from the catecholaminergic and serotoninergic neurons in the brain ('catecholaminergic/serotoninergic activity enhancer, CAE/SAE, effect'). (-)Deprenyl (Selegiline) and (-)1-phenyl-2-propylaminopentane [(-)PPAP] are amphetamine derived CAE substances devoid of the catecholamine releasing property. 2. By changing the aromatic ring in PPAP we developed highly potent and selective CAE/SAE substances, structurally unrelated to the amphetamines. Out of 65 newly synthetized compounds, a tryptamine derived structure, (-)1-(benzofuran-2-yl)-2-propylaminopentane [(-)BPAP] was selected as a potential follower of (-)deprenyl in the clinic and as a reference compound for further analysis of the CAE/SAE mechanism in the mammalian brain. 3. (-)BPAP significantly enhanced in 0.18 micromol 1(-1) concentration the impulse propagation mediated release of [(3)H]-noradrenaline and [(3)H]-dopamine and in 36 nmol 1(-1) concentration the release of [(3)H]-serotonin from the isolated brain stem of rats. The amount of catecholamines and serotonin released from isolated discrete rat brain regions (dopamine from the striatum, substantia nigra and tuberculum olfactorium, noradrenaline from the locus coeruleus and serotonin from the raphe) enhanced significantly in the presence of 10(-12) - 10(-14) M (-)BPAP. BPAP protected cultured hippocampal neurons from the neurotoxic effect of beta-amyloid in 10(-14) M concentration. In rats (-)BPAP significantly enhanced the activity of the catecholaminergic and serotoninergic neurons in the brain 30 min after acute injection of 0.1 microg kg(-1) s.c. In the shuttle box, (-)BPAP in rats was about 130 times more potent than (-)deprenyl in antagonizing tetrabenazine induced inhibition of performance.Keywords
This publication has 30 references indexed in Scilit:
- Is there a “non-MAO” macromolecular target for L-rmdeprenyl?: Studies on MAOB mutant miceLife Sciences, 1998
- Treatment with L-deprenyl prolongs life in elderly dogsLife Sciences, 1997
- Phenylethylamine and tyramine are mixed-acting sympathomimetic amines in the brainLife Sciences, 1996
- (−)Deprenyl and (−)1-phenyl-2-propylaminopentane, [(−) PPAP] act primarily as potent stimulants of action potential — transmitter release coupling in the catecholaminergic neuronsLife Sciences, 1996
- Enhanced catecholaminergic and serotoninergic activity in rat brain from weaning to sexual maturity: Rationale for prophylactic (-)deprenyl (selegiline) medicationLife Sciences, 1995
- Sexually low performing male rats die earlier than their high performing peers and (-)deprenyl treatment eliminates this differenceLife Sciences, 1994
- Chronic treatment of (-)deprenyl prolongs the life span of male fischer 344 rats. Further evidenceLife Sciences, 1993
- Maintenance on l-deprenyl prolongs life in aged male ratsLife Sciences, 1990
- Striatal dopamine, sexual activity and lifespan. Longevity of rats treated with (-) deprenylLife Sciences, 1989
- L-deprenyl, a selective monoamine oxidase type-b inhibitor in endogenous depressionLife Sciences, 1980